Dr. Steven Theriault reports

CYTOPHAGE ANNOUNCES MAILING OF ANNUAL AND SPECIAL MEETING MATERIALS WITH BOARD NOMINEES

Cytophage Technologies Ltd. has mailed meeting materials relating to its annual and special meeting of shareholders to be held on Wednesday, June 25, 2025, at 3:15 p.m. Winnipeg time (4:15 p.m. Toronto time) at 400 Fort Whyte Way, Unit 200A, Oak Bluff, Man.

The following individuals comprise the board slate for the ASM: Dr. Steven Theriault, Robert Gabor, Michael Sorkin, John Snisarenko, Michael D. Cochrane and William Ollerhead, who are standing for re-election, and a new nominee, Thomas (Tom) Wellner.

Cytophage's board of directors selected Mr. Wellner to stand for election to the board based on his leadership experience in biotechnology and pharmaceutical companies, in-depth governance experience, and extensive global business network. Mr. Wellner is a highly experienced corporate executive with over three decades of global experience in biotechnology, pharmaceutical and health care service companies. Following a successful 20-year global career with Eli Lilly, Mr. Wellner led several health care organizations, including Lilly Germany, LifeLabs/CML Healthcare and Therapure Biopharma. He recently retired as president and chief executive officer of Revera Inc., a leading global owner, operator and developer in the senior living/health care sector.

Mr. Wellner currently serves on the board of Andlauer Health Group, where he chairs the audit committee. He also currently serves on the board of the Ontario Teachers Pension Plan, has previously served on the boards of FreshBooks, Novadaq Technologies, Cipher Pharmaceuticals, Diamedica and various Revera Inc. entities, and has been an adviser to a variety of private equity, venture capital funds and family offices. He has his ICD.D directors designation from the Rotman School of Business, and has been a guest lecturer on international business and health care at Harvard, Rotman and INSEAD schools of business. He is also a published author.

Michael Sorkin, vice-chair of Cytophage's board of directors, commented: "We have been in active discussions with Tom Wellner over the past few months and are excited that Tom will stand for election to our board. As a seasoned executive in health care circles, Tom brings a wealth of governance and operating experience that will help accelerate Cytophage's business strategy."

Cytophage's current chairman, Harold Wolkin, and current director Dr. Shantha Kodihalli, who have both diligently served the board since 2020, will not stand for re-election.

Cytophage chief executive officer Dr. Steven Theriault commented: "We are tremendously grateful to Harold for his steady leadership and guidance, especially during the past pivotal two years for Cytophage. We wish Harold the best in all of his endeavours. Shantha has also made invaluable contributions to Cytophage in her position as director, offering seminal scientific advice and insights. We thank her for her dedication."

The ASM materials are available on the Cytophage website and have also been filed under the company's profile on SEDAR+.

Due to the potential Canadian postal disruption, shareholders requiring assistance in voting their shares or to obtain replacement proxy materials are encouraged to contact Cytophage's proxy solicitation agent and shareholder communications adviser, TMX Trust, by e-mailing investor services at tsxtis@tmx.com.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular- or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health, which offers a fast track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance. The World Health Organization predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production, including 27 European Union countries, United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.